Effects of vasopressin and antihyperkalemic treatments on hemodynamics, potassium concentration, and resuscitation success in a porcine hyperkalemic cardiac arrest model Authors: Wan Young Heo, Hyoung Youn Lee, Najmiddin Mamadjonov, Hussain Ahmad, Yeon Heo, Yong Hun Jung, Seok Jin Ryu, Byung Kook Lee, Kyung Woon Jeung Published: 2026 ABSTRACT AbstractVasopressin may improve blood flow during cardiopulmonary resuscitation (CPR) in hyperkalemic cardiac arrest. This could enhance the delivery of antihyperkalemic treatments and improve potassium-lowering effects and resuscitation outcomes. We assessed the effects of vasopressin and epinephrine, with and without antihyperkalemic treatments, on hemodynamics, laboratory parameters, and return of spontaneous circulation (ROSC) in a porcine model of hyperkalemic cardiac arrest. After inducing hyperkalemic cardiac arrest with potassium administration, 40 pigs were randomized into four groups: (1) epinephrine + saline placebo, (2) epinephrine + antihyperkalemic treatments, (3) vasopressin + saline placebo, and (4) vasopressin + antihyperkalemic treatments. Vasopressin (P = 0.004) and antihyperkalemic treatments (P = 0.042) significantly improved coronary perfusion pressure (CoPP) during CPR compared to epinephrine and saline placebo, respectively. Neither showed differences in potassium concentration during CPR compared to their respective controls. There was no significant interaction between vasopressor type and antihyperkalemic treatments for CoPP or potassium levels. Vasopressin and antihyperkalemic treatments significantly increased the odds of ROSC compared to epinephrine and saline placebo, respectively (both P = 0.017), with the highest ROSC rate in the combined treatment group. In conclusion, vasopressin improved ROSC through superior CoPP compared to epinephrine, without enhancing the potassium-lowering effects of antihyperkalemic treatments.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-55405-z.Keywords: Hyperkalemia, Heart arrest, Cardiopulmonary resuscitation, Vasopressin, Antihyperkalemic agentsSubject terms: Cardiology, Diseases, Medical research, Physiology Introduction Hyperkalemia is becoming increasingly common due to the rising prevalence of chronic kidney disease and the growing use of potassium-modulating agents, such as renin-angiotensin-aldosterone system inhibitors1. Severe hyperkalemia, a medical emergency that can cause life-threatening arrhythmias such as ventricular fibrillation (VF) and cardiac standstill, frequently occurs in patients with impaired renal function2. Hyperkalemic cardiac arrest accounts for approximately 10–20% of in-hospital cardiac arrests and an even higher proportion among patients with advanced kidney disease3–5. Prognosis is poor, as evidenced by low rates of sustained return of spontaneous circulation (ROSC) and survival following hyperkalemic in-hospital cardiac arrest3. Therefore, identifying and implementing treatments to improve outcomes in hyperkalemic cardiac arrest is essential. Current international resuscitation guidelines recommend antihyperkalemic treatments alongside standard advanced cardiovascular life support (ACLS) for hyperkalemic cardiac arrest6,7. In our recent study comparing hemodynamic, echocardiographic, and brain tissue oxygen tension (PbtO2) measurements during ACLS in hyperkalemic and VF cardiac arrests in pigs, we found lower coronary perfusion pressure (CoPP) in hyperkalemic arrest, suggesting that epinephrine’s pressor effect was attenuated relative to VF arrest8. When coronary arteries are patent, myocardial perfusion during cardiopulmonary resuscitation (CPR) is primarily determined by CoPP9. Consequently, reduced CoPP in hyperkalemic cardiac arrest may impair myocardial perfusion, limiting delivery of antihyperkalemic agents to the heart and diminishing their effectiveness during CPR. Given its ability to improve vital organ blood flow during CPR compared with epinephrine in non-hyperkalemic animal models10–12, vasopressin may enhance perfusion and the efficacy of antihyperkalemic therapies in hyperkalemic cardiac arrest. However, we could find no studies examining the interaction between vasopressors and antihyperkalemic treatments, or the impact of vasopressin on resuscitation outcomes in this context. In the present study, we investigated the effects of vasopressin and epinephrine, with and without antihyperkalemic therapy, on hemodynamic and laboratory parameters during CPR and ROSC in a porcine model of hyperkalemic cardiac arrest. We hypothesized that vasopressin would facilitate ROSC not only through its pressor effects but also by enhancing the potassium-lowering efficacy of antihyperkalemic treatments. Materials and methods A total of 40 healthy male Yorkshire/Landrace cross pigs (2.5 to 3 months old, 24.0 ± 2.2 kg) were used in this prospective, randomized 2 × 2 factorial study. The Animal Care and Use Committee of Chonnam National University Hospital approved this study (CNUH IACUC-24017), and all animal care and procedures were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Furthermore, this study was conducted and reported in compliance with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines. The investigators who performed the experiments had completed an Institutional Animal Care and Use Committee training course on animal care and handling. All surgical procedures were performed under sevoflurane anesthesia, and every effort was made to minimize animal distress. Preparation Animals were purchased for the experiment from a local farm via the Chonnam National University Hospital Biomedical Research Institute. They arrived at the laboratory one week prior to the experiments and underwent a 7-day acclimation period. They were fasted for approximately 10 h but had free access to water. Sedation was induced with an intramuscular injection of ketamine (20 mg/kg) and xylazine (2.2 mg/kg). Animals were then placed in dorsal recumbency, anesthetized with inhaled sevoflurane (5%), intubated with a 7.0-mm internal diameter tracheal tube, and ventilated with a 7:3 mixture of nitrous oxide and oxygen using a ventilator/anesthesia machine. During surgical preparation, anesthesia was maintained with sevoflurane, adjusted to prevent signs of distress (withdrawal reflex, increased heart rate or arterial pressure). Tidal volume and respiratory rate were modified to maintain end-tidal carbon dioxide (ETCO2) between 35 and 45 mmHg. Electrodes were attached to the chest wall for electrocardiogram monitoring. Body temperature was monitored via a rectal probe, and a heating blanket or fan was used to maintain temperature between 37 and 38 °C. A 7-F catheter was inserted into the right femoral artery for blood sampling and arterial pressure monitoring. Simultaneously, a 7-F catheter was placed in the right external jugular vein for right atrial (RA) pressure monitoring and infusion of 0.9% sodium chloride (5 mL/kg/h). The animals were then placed in the prone position. The skin over the fourth lumbar vertebra was locally anesthetized with lidocaine, followed by a sterile incision and laminectomy to expose the dura mater. A 20 G catheter was inserted through the dura to measure cerebrospinal fluid (CSF) pressure, a surrogate for intracranial pressure13. A burr hole was created in the skull 1 cm posterior to the coronal suture and 1 cm right lateral to the sagittal suture. An optical oxygen sensor (PreSens-Precision Sensing GmbH, Regensburg, Germany) was inserted through the burr hole for PbtO2 monitoring and sealed with bone cement to prevent CSF leakage. Animals were randomly assigned using sealed envelopes to one of four groups, and blinded syringes were prepared with the following treatments: (1) epinephrine + saline placebo (Epi + Sal group); (2) epinephrine + antihyperkalemic treatments (Epi + Anti-K group); (3) vasopressin + saline placebo (Vaso + Sal group); and (4) vasopressin + antihyperkalemic treatments (Vaso + Anti-K group). Experimental protocol Baseline potassium was adjusted to 4.5 mEq/L by infusing potassium chloride at a dose calculated as ([4.5 mEq/L – measured potassium] × body weight), based on arterial blood sampled immediately after femoral artery catheterization. After baseline measurements, hyperkalemia was induced by administering potassium chloride at 2.8 mEq/kg/h for 45 min, followed by a 0.3 mEq/kg bolus to induce cardiac arrest (Fig. 1)14. Immediately following cardiac arrest, sevoflurane and mechanical ventilation were discontinued, and animals remained untreated for 8 min. After 8 min of untreated cardiac arrest, basic life support (BLS) was initiated with cycles of 30 mechanical chest compressions (Life-Stat, Michigan Instruments, Grand Rapids, MI, USA) followed by two bag ventilations with ambient air. Compressions were delivered at 100/min to a depth of ~ 20% of the anterior-posterior chest diameter. After 2 min of BLS, ACLS was initiated. Ventilations were then delivered at 10 breaths/min using 15 L/min of oxygen. Cardiac rhythm was assessed every 2 min, and biphasic 200 J defibrillation was performed if indicated. After 1 min of ACLS, animals received either epinephrine (0.02 mg/kg) or vasopressin (0.4 U/kg) per group assignment; doses were repeated every 4 min until ROSC was achieved. Following the first rhythm analysis (2 min into ACLS), animals in the antihyperkalemic treatment groups received antihyperkalemic therapies (sodium bicarbonate 1 mmol/kg intravenously over 5 min; regular insulin 0.1 unit/kg with 25% dextrose 2 mL/kg intravenously over 15 min; albuterol 5 mg nebulized inhalation), while the saline placebo groups received equivalent volume of saline administered intravenously and via nebulization. We selected standard experimental doses of epinephrine and vasopressin used in porcine models15–17, and clinically relevant doses of sodium bicarbonate, insulin with dextrose, and nebulized albuterol. Calcium was excluded based on recent studies showing no benefit or possible harm in hyperkalemic cardiac arrest14,18,19. CPR continued until ROSC, which is defined as an organized rhythm with systolic arterial pressure > 60 mmHg, or for a maximum of 30 min from BLS initiation. Animals achieving ROSC were reconnected to the ventilator/anesthesia machine and ventilated with 100% oxygen. After 15 min, inspired oxygen was reduced to 50%, and sevoflurane was titrated to maintain adequate anesthesia depth. Norepinephrine was administered as needed to maintain mean arterial pressure (MAP) ≥ 65 mmHg. Animals were continuously monitored for 1 h post-ROSC. Blood samples were then collected, and the animals were humanely euthanized with 40 mEq intravenous potassium under 5% sevoflurane. Predetermined humane endpoints were: (1) seizure; (2) systolic arterial pressure < 60 mmHg; and (3) heart rate < 40 bpm. Animals meeting any endpoint were immediately euthanized as described. An autopsy was conducted to identify CPR-related injuries (e.g., pneumothorax, hemothorax, hemoperitoneum) that could influence hemodynamic data. Experimental timeline. In total, 40 animals were randomized into four groups: (1) epinephrine + saline placebo, (2) epinephrine + antihyperkalemic treatments, (3) vasopressin + saline placebo, (4) vasopressin + antihyperkalemic treatments. The lightning marks indicate 10 s chest compression pause for rhythm analysis and a biphasic 200 J electric countershock, if indicated. IV, intravenous; CA, cardiac arrest; BLS, basic life support; ACLS, advanced cardiovascular life support; ROSC, return of spontaneous circulation. Measurements Aortic, RA, and CSF pressures were recorded using a hemodynamic monitor (CS/3 CCM, Datex-Ohmeda, Helsinki, Finland) and transferred to a computer via S/5 Collect Software (Datex-Ohmeda, Helsinki, Finland). Data were sampled at baseline, every 1 min during CPR, and every 5 min post-ROSC. Cerebral perfusion pressure (CePP) was calculated as MAP minus CSF pressure. CoPP was calculated as aortic end-diastolic pressure minus RA end-diastolic pressure. PbtO2 was measured using an optical oxygen sensor connected to an oxygen meter (OXY-1 ST; PreSens‐Precision Sensing GmbH) and sampled at baseline, 1-min intervals during CPR, and 5-min intervals post-ROSC. Next, 2 mL of blood were collected from the femoral arterial catheter for analysis of blood gases, glucose, lactate, and electrolytes at baseline, after hyperkalemia induction (before cardiac arrest), every 4 min during CPR from the onset of ACLS, immediately after ROSC, and at 1 h post-ROSC in animals that achieved ROSC. pH-corrected potassium concentrations were calculated using the method described by Burnell et al.20. Statistical analysis Sample size estimation was based on the ROSC rate as the primary outcome, using a chi-square test for contingency tables. A total sample size sufficient to detect a medium-to-large effect (Cohen’s ω = 0.467) with 80% power and α = 0.05 was calculated. The effect size was derived from a study by Eggertsen et al.14, in which sodium bicarbonate significantly improved ROSC rates compared to saline (24/26 [92%] vs. 13/26 [50%]) in a porcine model of hyperkalemic cardac arrest. With one degree of freedom, the analysis indicated a total required sample size of 36 animals. This was increased to 40 animals to account for potential data loss. Statistical analyses were conducted using R version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria) and T&F program version 4.5 (YooJin BioSoft, Goyang, Korea). Continuous variables were reported as mean ± standard deviation or median (interquartile range). Between-group comparisons of continuous variables were performed using the independent two-sample t-test or Wilcoxon rank-sum test, as appropriate. Categorical variables were expressed as count (proportion), and group comparisons were performed using Fisher’s exact test. For comparisons among the four groups, one-way analysis of variance (ANOVA) or Kruskal–Wallis H test was used for continuous variables, and Fisher’s exact test was used for categorical variables, with Bonferroni correction applied for post hoc analyses. Two-way ANOVA and binary logistic regression were used to assess the effects of vasopressor type, antihyperkalemic treatments, and their interaction on continuous and categorical variables, respectively. For non-normally distributed continuous data, an Aligned Rank Transform was applied prior to two-way ANOVA. Linear mixed-effects models were generated to analyze the fixed effects of vasopressor type, antihyperkalemic treatments, and their interactions on repeated measures, accounting for random effects. A two-tailed P-value of < 0.05 was considered statistically significant for all analyses. Results All 40 animals successfully completed the study protocol and were included in the analysis, as autopsies confirmed the absence of internal organ injury in all cases. With the exception of heart rate, baseline measurements did not differ among the four groups, between epinephrine and vasopressin groups, or between saline placebo and antihyperkalemic treatment groups (Supplementary Tables S1 and S2). Heart rates were lower in the Vaso + Sal group than in the Vaso + Anti-K group and also lower in the saline placebo groups than in the antihyperkalemic treatment groups, but remained within normal limits in all animals. Supplementary Tables S3 and S4 show the hemodynamic data and potassium concentrations measured immediately following the 45-min potassium chloride infusion. This infusion increased potassium concentration to 9.3 ± 0.8 mEq/L, with no significant differences among the four groups, between epinephrine and vasopressin groups, or between saline placebo and antihyperkalemic treatment groups. All animals experienced cardiac arrest with a non-shockable rhythm after receiving a bolus injection of 0.3 mEq/kg potassium chloride; however, VF was subsequently observed in all animals at least once during ACLS. Figure 2 and Supplementary Fig. S1 display CoPP, CePP, ETCO2, and PbtO2 during CPR. No significant interaction was observed between vasopressor type and antihyperkalemic treatments for these variables. Compared to epinephrine, vasopressin significantly improved CoPP (coefficient, 30.799 [95% CI {confidence interval}, 11.567–50.031]; P = 0.003), CePP (35.408 [95% CI, 12.895–57.921]; P = 0.004), and PbtO2 (10.607 [95% CI, 3.559–17.656]; P = 0.006). Antihyperkalemic treatments significantly increased CoPP (20.534 [95% CI, 1.478–39.590]; P = 0.042) compared to saline placebo but did not affect CePP or PbtO2. Neither vasopressor type nor antihyperkalemic treatments significantly affected ETCO2. Figures 3 and 4 and Supplementary Fig. S2 show blood gases, glucose, lactate, and electrolytes during CPR. No significant interaction was observed between vasopressor type and antihyperkalemic treatments for these variables. Antihyperkalemic treatments significantly increased pH (0.096 [95% CI, 0.038–0.154]; P = 0.003), PaCO2 (10.788 [95% CI, 3.098–18.478]; P = 0.009), bicarbonate (8.718 [95% CI, 5.985–11.451]; P < 0.001), and glucose (138.113 [95% CI, 61.161–215.064]; P = 0.001) compared to saline placebo. Vasopressin significantly reduced lactate compared to epinephrine (− 0.983 [95% CI, − 1.823 to − 0.144]; P = 0.028). Neither vasopressor type nor antihyperkalemic treatments affected PaO2, sodium, potassium, or pH-corrected potassium. CoPP, CePP, ETCO2, and PbtO2 during cardiopulmonary resuscitation. (a,c,e,g) epinephrine vs. vasopressin groups. (b,d,f,h) saline placebo vs. antihyperkalemic treatment groups. Data are presented as mean ± standard deviation. Although CoPP and PbtO2 data were non-normally distributed at most time points, they are shown using mean ± standard deviation line plots to clearly illustrate trends over time. P values were computed using linear mixed-effects models. The number of animals receiving CPR at each time point is shown in Supplementary Table S7. The interaction P values for vasopressor type × antihyperkalemic treatments were 0.673, 0.539, 0.273, and 0.580 for CoPP, CePP, ETCO2, and PbtO2, respectively. For one animal in the Vaso + Sal group and two animals in the Vaso + anti-K group, PbtO2 was unmeasurable due to sensor displacement during cardiopulmonary resuscitation. CoPP, coronary perfusion pressure; CePP, cerebral perfusion pressure; ETCO2, end-tidal carbon dioxide; PbtO2, brain tissue oxygen tension. pH, PaCO2, PaO2, and bicarbonate during cardiopulmonary resuscitation. (a,c,e,g) epinephrine vs. vasopressin groups. (b,d,f,h) saline placebo vs. antihyperkalemic treatment groups. Data are presented as mean ± standard deviation. Although PaO2 data were non-normally distributed at most time points, they are shown using mean ± standard deviation line plots to clearly illustrate trends over time. P values were computed using linear mixed-effects models. The number of animals receiving CPR at each time point is shown in Supplementary Table S7. The interaction P values for vasopressor type × antihyperkalemic treatments were 0.105, 0.071, 0.748, and 0.453 for pH, PaCO2, PaO2, and bicarbonate, respectively. PaCO2, arterial carbon dioxide tension; PaO2, arterial oxygen tension. Sodium, potassium, glucose, and lactate during cardiopulmonary resuscitation. (a,c,e,g) epinephrine vs. vasopressin groups. (b,d,f,h) saline placebo vs. antihyperkalemic treatment groups. Data are presented as mean ± standard deviation. Although potassium data were non-normally distributed at most time points, they are shown using mean ± standard deviation line plots to clearly illustrate trends over time. P values were computed using linear mixed-effects models. The number of animals receiving CPR at each time point is shown in Supplementary Table S7. The interaction P values for vasopressor type × antihyperkalemic treatments were 0.080, 0.762, 0.426, and 0.101 for sodium, potassium, glucose, and lactate, respectively. ROSC and 1-h survival were achieved in three animals (30%) in the Epi + Sal group, 7 (70%) in the Epi + Anti-K group, 7 (70%) in the Vaso + Sal group, and 10 (100%) in the Vaso + Anti-K group. No animals reached the predetermined humane end points for euthanasia until the completion of the 1 h post-ROSC period. In the binary logistic regression analysis, vasopressin significantly increased the odds of ROSC compared with epinephrine (odds ratio, 8.197 [95% CI, 1.454–45.455]; P = 0.017). Antihyperkalemic treatments likewise increased the odds of ROSC compared with saline placebo (odds ratio, 8.197 [95% CI, 1.454–45.455]; P = 0.017). However, the 100% ROSC rate in the Vaso + Anti-K group resulted in an infinite CI in the logistic regression model, precluding formal estimation of the interaction between vasopressor type and antihyperkalemic treatments for ROSC. Pairwise comparisons using Fisher’s exact test with Bonferroni correction showed that the Vaso + Anti-K group had a significantly higher likelihood of ROSC than the Epi + Sal group (odds ratio, 45.000 [95% CI, 2.011–1006.804]; P = 0.009). Although the Epi + Anti-K and Vaso + Sal groups demonstrated numerically higher ROSC rates (70%), these differences were not statistically significant compared with the Epi + Sal group. In total, 32 animals reached the commonly cited CoPP threshold of > 15 mmHg necessary for ROSC during CPR21. Among these, five of 15 (33%) in the saline placebo group and one of 17 (6%) in the antihyperkalemic treatment group failed to achieve ROSC (Supplementary Table S5). Supplementary Table S6 presents resuscitation parameters in successfully resuscitated animals. No significant interactions were found between vasopressor type and antihyperkalemic treatments regarding CPR duration or the number of defibrillations. Vasopressin (P = 0.038) and antihyperkalemic treatments (P = 0.007) significantly reduced CPR duration compared to epinephrine and saline placebo, respectively. Neither vasopressor type nor antihyperkalemic treatments influenced the number of defibrillations. Supplementary Table S7 shows the number of animals receiving CPR at each time point. Supplementary Table S8 shows blood gases, glucose, lactate, and electrolytes immediately after ROSC. Potassium concentration at this time was not significantly affected by either vasopressor or antihyperkalemic treatment. Figure 5 and Supplementary Fig. S3 show MAP, heart rate, and PbtO2 during the 1 h post-ROSC period. No significant effects of vasopressor type, antihyperkalemic treatment, or their interaction were observed. Neither vasopressor type nor antihyperkalemic treatments affected the dose or duration of norepinephrine administration (Supplementary Table S9). Supplementary Table S10 shows the blood gases, glucose, lactate, and electrolytes measured at 1 h after ROSC. Compared to saline placebo, antihyperkalemic treatments significantly increased PaCO2 (P = 0.034) and sodium concentration (P < 0.001) and reduced potassium (P < 0.001) at 1 h post-ROSC. Epinephrine was associated with a lower potassium concentration at 1 h post-ROSC compared to vasopressin (P = 0.046). MAP, heart rate, and PbtO2 during the 1 h post-resuscitation period. (a,c,e) epinephrine vs. vasopressin groups. (b,d,f) saline placebo vs. antihyperkalemic treatment groups. Data are presented as mean ± standard deviation. Although MAP and heart rate data were non-normally distributed at most time points, they are shown using mean ± standard deviation line plots to clearly illustrate trends over time. P values were computed using linear mixed-effects models. The interaction P values for vasopressor type × antihyperkalemic treatments were 0.778, 0.500, and 0.893 for MAP, heart rate, and PbtO2, respectively. For two animals in the Vaso + anti-K group, PbtO2 was unmeasurable due to sensor displacement. MAP, mean arterial pressure; PbtO2, brain tissue oxygen tension. Discussion The present study examined the effects of vasopressin and epinephrine, both with and without antihyperkalemic treatments, on hemodynamic and laboratory parameters during CPR and ROSC in a porcine model of hyperkalemic cardiac arrest. While vasopressin and antihyperkalemic treatments improved CoPP during CPR compared to their respective controls, neither affected potassium concentration during CPR. Additionally, no significant interaction between vasopressor type and antihyperkalemic treatments was observed for either CoPP or potassium levels. Importantly, while binary logistic regression demonstrated that each intervention significantly contributed to the likelihood of ROSC, direct group comparisons indicated that the highest ROSC rate was achieved with the combined use of vasopressin and antihyperkalemic treatments. Although the 100% ROSC rate in the Vaso + Anti-K group precluded formal statistical evaluation of an interaction for ROSC, the CoPP data strongly support an additive physiological effect of the two interventions. Because neither treatment influenced potassium concentrations during CPR, the observed improvement in ROSC appears to be primarily mediated by enhanced CoPP. The absence of a significant interaction for CoPP further indicates that the effects of vasopressin and antihyperkalemic treatments on coronary perfusion are independent. Accordingly, the superior ROSC rate in the Vaso + Anti-K group most likely reflects the cumulative benefit of improved coronary perfusion rather than a true synergistic or antagonistic interaction. Nevertheless, larger studies are warranted to more definitively assess potential interactions between these two interventions. Consistent with our recent findings of reduced pressor response to epinephrine in hyperkalemic cardiac arrest compared to VF arrest8, the Epi + Sal group showed markedly low CoPP during CPR and a correspondingly low rate of ROSC. Aligning with previous studies in non-hyperkalemic animal models that demonstrated vasopressin’s superiority over epinephrine in improving CoPP and facilitating ROSC10,12, our study found that vasopressin was similarly effective in a hyperkalemic cardiac arrest model. Although direct comparisons of vasopressin’s pressor effect between hyperkalemic and non-hyperkalemic cardiac arrest are lacking, vasopressin may retain its efficacy better than epinephrine in hyperkalemic cardiac arrest. Metabolic acidosis and uremia, common in hyperkalemic cardiac arrest from renal dysfunction, attenuate epinephrine’s effects but not those of vasopressin22. While current resuscitation guidelines recommend incorporating antihyperkalemic treatments into standard ACLS for hyperkalemic cardiac arrest6,7, no universally standardized antihyperkalemic treatment protocols for use in this setting currently exist. Standard hyperkalemia management in non-arrest settings includes membrane stabilization (intravenous calcium), transcellular potassium shift (sodium bicarbonate, insulin with glucose, nebulized albuterol), and potassium elimination (furosemide or hemodialysis). In our study, we employed sodium bicarbonate, insulin with glucose, and nebulized albuterol, excluding hemodialysis due to limited feasibility in cardiac arrest, and calcium due to recent evidence suggesting no benefit or possible harm14,18,19. Antihyperkalemic treatments increased ROSC compared to the saline placebo, which aligns with previous studies3,14. In a porcine model of hyperkalemic cardiac arrest, Eggertsen et al. found that sodium bicarbonate reduced time to and improved rates of ROSC14. In our study, all animals initially showed a non-shockable rhythm, unlike the findings of Eggertsen et al., where VF was the predominant presenting rhythm14. While the exact reason for this discrepancy in the initial rhythm is unclear, it may be related to the higher severity of hyperkalemia achieved in our study (9.3 ± 0.8 mEq/L vs. medians of 8.6–8.8 mEq/L in the study by Eggertsen et al.), potentially due to our higher baseline potassium adjustment (4.5 mEq/L vs. 4.0 mEq/L). Initially, this severe hyperkalemia likely caused profound electrophysiological suppression of the myocardium, which later evolved into VF as resuscitation efforts progressed. In the study by Eggertsen et al.14, sodium bicarbonate promptly lowered potassium concentrations within 2 min of administration compared to the control. In contrast, antihyperkalemic treatments in this study did not significantly reduce potassium levels during CPR relative to placebo. However, a potassium-lowering effect emerged 1 h post-ROSC. Although no significant decrease in blood potassium was observed during CPR, the treatments may have reduced interstitial potassium concentration, which is more relevant to cardiac electrical activity, thus helping restore resting membrane potential and ion channel function in well-perfused myocardium. Poor perfusion during CPR may also have hindered equilibration between compartments, delaying observable reductions in blood potassium23. Within the subgroup of animals achieving CoPP > 15 mmHg, the treatments did not yield a statistically significant difference in ROSC rates. Nevertheless, a descriptive analysis of this subgroup revealed a notable numerical disparity: 5 of 15 (33%) in the saline placebo group failed to achieve ROSC, compared to only 1 of 17 (6%) in the antihyperkalemic treatment group. The subgroup data do not confirm a causal relationship, but the marked difference indicates a potential for myocardial electrical stabilization not yet seen in systemic blood potassium levels. Therefore, this hypothesis is speculative, and further investigation in a larger, adequately powered cohort is needed to validate it. Unexpectedly, our study showed that antihyperkalemic treatments improved CoPP during CPR, although the exact mechanism remains unclear. Sodium bicarbonate may have increased CoPP during CPR via correction of acidosis, improving vasopressor responsiveness24, although previous studies have reported no such effect14,25. While albuterol and insulin have vasodilatory actions, making it unlikely they increased CoPP26–28, acute hyperglycemia resulting from dextrose administration could induce vasoconstriction, thereby increasing CoPP29,30. Further research is needed to clarify these mechanisms. In our study, vasopressin significantly increased CePP and PbtO2 and lowered lactate concentrations during CPR compared to epinephrine, indicating that its superior pressor effect does not compromise cerebral perfusion. Post-ROSC, vasopressin did not adversely affect hemodynamics or PbtO2 compared to epinephrine, nor did it impact the need for norepinephrine. In our study, the potassium concentration at 1 h post-ROSC was higher in the vasopressin groups compared to the epinephrine groups, likely due to vasopressin’s lack of β-adrenergic activity and potassium-lowering effects, in contrast to epinephrine. These findings suggest that vasopressin may improve ROSC without adverse post-ROSC hemodynamic effects, though additional interventions may be required to manage persistent hyperkalemia. If these findings are confirmed in clinical studies, vasopressin may represent a more effective alternative to epinephrine when hyperkalemic cardiac arrest is suspected. Although pre-arrest electrocardiographic waveforms are mostly unavailable in clinical practice, suspicion of hyperkalemia in the hospital setting can be supported by point-of-care blood gas analysis, which is widely available in many emergency departments. In the prehospital setting, where such diagnostic capabilities are more limited, providers may instead rely on the identification of high-risk precipitating factors, such as a known history of chronic kidney disease, to guide clinical suspicion. Notably, previous randomized controlled trials have shown that vasopressin is non-inferior to epinephrine in the management of undifferentiated out-of-hospital cardiac arrest31,32. Accordingly, empirical use of vasopressin in cases of suspected hyperkalemic cardiac arrest may improve the likelihood of ROSC, while remaining unlikely to adversely affect outcomes if the arrest is subsequently determined to be non-hyperkalemic. Our study has several limitations. First, the use of young, healthy, anesthetized pigs limits generalizability to human patients, who often have comorbidities. Additionally, vasopressin receptor differences between pigs and humans may alter pressor responsiveness33. Second, hyperkalemia was induced pharmacologically, not via renal dysfunction or other underlying disease, which may influence treatment efficacy. Third, our study was powered to detect a 42% difference in ROSC rates, meaning that it may have been underpowered to identify secondary outcomes, such as potassium levels during CPR. Fourth, we only observed the animals for 1 h post-ROSC. This limited observation period is insufficient to assess clinically relevant outcomes such as neurological recovery and long-term survival, which should be emphasized when interpreting these results. Fifth, the concurrent administration of multiple antihyperkalemic agents made it impossible to determine each drug’s individual contribution. Conclusions In this porcine model of hyperkalemic cardiac arrest, vasopressin and antihyperkalemic treatments significantly improved CoPP during CPR and increased the odds of ROSC compared with epinephrine and saline placebo, respectively. The combined administration of vasopressin and antihyperkalemic treatments resulted in the highest ROSC rate, suggesting that this approach may provide the most effective hemodynamic support for achieving ROSC in this model. In the absence of a significant effect of either treatment on potassium concentrations during CPR and without evidence of a statistical interaction between the two interventions in CoPP, the superior resuscitation outcomes observed with the combination most likely reflect independent and additive physiological effects mediated by enhanced coronary perfusion. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Author contributions W.Y.H., H.Y.L., Y.H.J., and K.W.J. developed the methodology. H.Y.L., Y.H.J., and K.W.J. provided the necessary resources. W.Y.H., H.Y.L., N.M., H.A., Y.H., Y.H.J., and K.W.J. performed the investigation. Formal analysis was carried out by S.J.R. and B.K.L. W.Y.H., H.Y.L., N.M., H.A., Y.H., Y.H.J., S.J.R., B.K.L., and K.W.J. wrote the original draft preparation. K.W.J. was responsible for the conceptualization and writing-review & editing of the manuscript. All authors have read and agreed to the published version of the manuscript. Funding This study was supported by a grant (BCRZ25044) of Chonnam National University Hospital Biomedical Research Institute. Data availability The data and materials used in this study are available from the corresponding author upon reasonable request. Declarations Competing interests The authors declare no competing interests. Ethics statement This study was approved by the Animal Care and Use Committee of Chonnam National University Hospital (CNUH IACUC-24017) and conducted in compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The data and materials used in this study are available from the corresponding author upon reasonable request.